LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that Curis scientists and collaborators will present data from three programs at the Annual Meeting of American Association for Cancer Research (AACR) to be held from April 5th to 9th in San Diego, CA. Curis researchers will present data for two of its proprietary targeted cancer drug candidates, CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, an antagonist of IAP proteins.
Curis' partner Debiopharm will present data for Debio 0932, an orally-administered heat shock protein (HSP90) inhibitor.
Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.
| Poster Presentations: | |
| Date/Time: | Sunday, April 6, 2014, 1:00 PM - 5:00 PM |
| Location: | Hall A-E, Poster Section 37 |
| Session Title: | Predictive Biomarker 1 |
| Session Category: | Clinical Research 2 |
| Presentation Title: | Post-treatment changes in levels of TNF family ligands and XIAP may predict sensitivity to IAP antagonist CUDC-427 |
| Abstract Number: | 917 |
| Date/Time: | Monday, April 7, 2014, 8:00 AM - 12:00 PM |
| Location: | Hall A-E, Poster Section 37 |
| Session Title: | New Diagnostics, Therapeutic Targeting, and Response Assessments |
| Session Category: | Clinical Research 5 |
| Presentation Title: | Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies |
| Abstract Number: | 1879 |
| Date/Time: | Monday, April 7, 2014, 8:00 AM - 12:00 PM |
| Location: | Hall A-E, Poster Section 33 |
| Session Title: | Novel Targets 1 |
| Session Category: | Experimental and Molecular Therapeutics 14 |
| Presentation Title: | Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer |
| Abstract Number: | 1792 |
About Curis, Inc.
Curis is an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers. Curis is seeking to further the development of its pipeline of proprietary targeted cancer drug candidates, including CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, a small molecule antagonist of IAP proteins. Erivedge® is our most advanced asset and the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis-discovered HSP90 inhibitor, Debio 0932 is being studied in patients with advanced lung and kidney cancers by partner Debiopharm. For more information, visit Curis' website at www.curis.com.
CONTACT: For More Information:
Mani Mohindru, Ph.D.
Vice President, Corporate Strategy and Investor Relations
Curis, Inc.
617-503-6605
mmohindru@curis.com
Michael P. Gray
Chief Financial and Chief Business Officer
Curis, Inc.
617-503-6632
mgray@curis.com